Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

PTC Gambles On Success With Emflaza; Says Price Revision Is Needed

Mar 16 2017

• By Joseph Haas

group of businessman in black suit and holding red arrow down graph

Related Content

Marathon Gets Long-Known Duchenne Treatment On-Label, But Will Payers Respond?

Feb 10 2017

‘File Over Protest’ At US FDA: PTC To Pursue Rarely-Used Pathway For DMD Drug

Jan 10 2017

PTC Tumbles On Ataluren Failure In Cystic Fibrosis

Mar 02 2017

Related Companies

PTC Therapeutics, Inc.

Marathon Pharmaceuticals LLC

Additional Topics

Commercial Pricing Debate Deals Market Access Rare Diseases BioPharmaceutical

More from Business

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window